Objective: To assess the long-term outcome of epilepsy with auditory features (EAF) and to identify the clinical predictors for prognosis. Methods: The study involved consecutive EAF patients with a follow-up of ≥5 years. Terminal remission (TR) was defined as a period of ≥5 consecutive years of seizure freedom at the last follow-up. We used Kaplan-Meier estimate to calculate the cumulative time-dependent probability of conversion to TR. Logrank test and multivariate Cox regression analyses were performed to study the association between time to TR and prognostic determinants. Results: We included 123 EAF patients (male/female = 58/65) with a median follow-up of 11 years (1626.9 person-years). Most were sporadic cases (68.3%), whereas 31.7% reported a family history of epilepsy. At last assessment, 42 patients had achieved TR (34.1%). Of the remaining 81 cases with no TR (65.9%), 37% had been in remission for 1-4 years and 62.9% still had seizures within the past year. The cumulative rates of TR were 26.6%, 35.7%, and 51.6% at 10, 20, and 30 years from inclusion. On multivariate analysis, age at onset > 10 years (hazard ratio [HR] = 3.2, P = .028), auditory aura characterized by distortions only versus simple/complex hallucinations (HR = 2.9, P = .041), and unremarkable scalp electroencephalogram (EEG) versus EEG with focal epileptiform activity (HR = 3.5, P = .041) were associated with TR. Significance: Our data show a wide prognostic spectrum of EAF, ranging from mild forms with spontaneous remission, to severely refractory epilepsy addressed to surgery. The outcome, less favorable than expected from previous studies, appears to be primarily a function of 3 prognostic negative risk factors: age at onset < 10 years, auditory aura characterized by complex auditory hallucinations, and focal epileptiform abnormalities on scalp EEG. These predictors, easy to collect even at the first visit, may inform both clinicians and patients about the longterm prognosis and aid patient management.
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| INTRODUCTION
Epilepsy with auditory features (EAF) is a focal epilepsy syndrome characterized by seizures with auditory aura or receptive aphasia suggesting a lateral temporal lobe onset, so that the term lateral temporal lobe epilepsy (TLE) has also been used. 1 The etiological factors underlying EAF are largely unknown but specific genetic forms with autosomal dominant (AD) inheritance (ADEAF or ADTLE) have been reported, mainly due to LGI1 and RLN mutations. [2] [3] [4] Overall, mutations in the genes identified so far cumulatively explain <50% of ADEAF families and <2% of sporadic cases. [5] [6] [7] [8] However, there are no significant differences in clinical features between sporadic cases and the familial form, independently from the genetic background. 9, 10 So far, ADEAF has been proposed as a paradigm of a distinct benign focal epilepsy syndrome occurring in patients of normal intelligence, normal brain magnetic resonance imaging (MRI), and good drug response. 6, 7, 11, 12 The largest case series on sporadic EAF suggested an overall good outcome but with a high relapsing rate after drug withdrawal. 10 Drug-resistant cases 13, 14 and patients with psychiatric comorbidity 14 are confined to anecdotal reports. Epilepsy remission, defined as a completely seizure-free status, possibly without treatments, is the most relevant goal for patients and physicians. Estimating the probability of conversion to remission and therefore being able to predict it early after the diagnosis would be valuable to clarify both the nature of EAF and its expected course. The current literature provides little prognostic value for individual patients.
To our knowledge, studies systematically addressing the long-term outcome of the whole spectrum of EAF syndrome are lacking, and the prognostic data are poor and derive from noncohort studies or from subpopulations of EAF patients.
We aimed to assess the long-term outcome, in terms of 5-year seizure freedom (SF) rate (terminal remission [TR] ), in a large cohort of consecutive patients diagnosed with EAF. In addition, we analyzed the clinical predictors for TR.
| MATERIALS AND METHODS
This study has a retrospective cohort design, and is reported following the STROBE guidelines. 15 
| Participants, setting, and eligibility criteria
The study, approved by the Local Ethics Committee (10077), was conducted between December 2014 and December 2016 at our institute. We reconstructed the initial pool of 219 patients ( Figure 1 ) reviewing medical records of all consecutive patients referred to the Epilepsy Center between 1975 and December 2016 with a history of suspected epileptic seizures with auditory aura and/or receptive aphasia. Data were collected in an ad hoc database. Details on database items, definitions, and methods of data collection are provided as supporting information (Appendices S1 and S2).
| Inclusion criteria and classification
We included patients of both genders and any age with (1) a diagnosis of EAF (clinical history of at least 2 lifetime seizures with auditory and/or aphasic features as first symptoms), (2) unremarkable neuroimaging (absence of epilepsyrelated lesions), and (3) a follow-up period of ≥5 years. According to family history, we defined familial cases as those with at least 1 relative within 2 degrees of kinship affected with EAF or other epilepsy. Families with at least 2 EAF-affected members were defined as ADEAF. Cases with a negative family history were defined as sporadic.
| Data collection
A medical chart recording clinical and instrumental updates at every control visit was reviewed for each patient. The
Key Points
• The prognostic spectrum of epilepsy with auditory features is wide, ranging from mild forms with spontaneous remission to severely refractory epilepsy addressed to surgery
• The outcome of EAF is less favorable than expected from previous studies, with only 34.1% of EAF patients achieving terminal remission
• Negative prognostic risk factors are: age at onset <10 years, auditory aura characterized by complex auditory hallucinations, and focal epileptiform abnormalities on scalp EEG last assessment was conducted by a direct outpatient (or inpatient) visit by December 2016. Patients unable to attend a control visit during the recruitment period were contacted by telephone and, after giving consent, underwent a semistructured telephone interview. The last assessment was focused principally on SF, ascertaining seizure frequency over the preceding 5 years, current antiepileptic drugs (AEDs), drug withdrawal, and surgical treatment. These data were collected directly from each patient and, whenever possible, from witnesses.
In addition, we collected genetic data on a subsample of patients who underwent screening for mutations in the major genes involved in the syndrome (LGI1, RLN, SCN1A, and DEPDC5) by different approaches (Sanger sequencing, next generation sequencing epilepsy gene panel, molecular inversion probes targeted sequencing, and whole exome sequencing).
| Outcomes and prognostic factors
The primary endpoint was TR, defined as a period of at least 5 consecutive years without seizures at the last follow-up, irrespective of treatment status, according to the definition of the International League against Epilepsy Commission on Epidemiology and Prognosis (1993) . 16 On the basis of the primary endpoint, patients were divided into 2 groups:
• TR group: patients seizure-free for ≥5 years at last visit;
• NTR group: patients not attaining TR.
We distinguished 3 basic patterns of seizure occurrence over time: (1) a "remitting pattern" for patients who achieved TR at some point in their disease history without any relapse; (2) a "continuous pattern" for patients having no remission at all after epilepsy onset; and (3) an "intermittent pattern" (including a "relapse-remitting" and a "remitting-relapse" course, depending on the final outcome), where their epilepsy course presented relapsing periods. Relapse was defined as the occurrence of any seizure after a 5-year remission had been achieved during the epilepsy course. 17 Potential prognostic factors were examined (Table 1) . Auditory aura was divided into distortions only (negative/positive) and hallucinations (simple/complex). 18 Time to diagnosis was defined as the temporal gap between seizure onset and the recognition of the correct epileptic syndrome. Diagnosis was dated from recognition of seizures with auditory features or diagnosis of "focal epilepsy," even if not better specified, followed by prescription of appropriate antiepileptic treatment (ie, carbamazepine). In patients whose diagnostic workup took longer than 1 year (time to diagnosis > 1 year), we quantified the diagnostic delay, ascribed to 2 possible factors: misdiagnosis and time to medical counseling. For the diagnostic delay, we arbitrarily fixed a period longer than 1 year, considering this the maximum time needed in the diagnostic workup for a reliable diagnosis of epilepsy at onset.
| Statistical analysis
Continuous variables are presented as mean AE standard deviation, and categorical variables as absolute and relative frequency (%). Student t test and Fisher's exact test were used to compare variables among the TR group and the NTR group. The cumulative time-dependent probability of conversion to TR state was calculated by the Kaplan-Meier estimate. The time of entry into the analysis was the date of diagnosis of focal epilepsy, and the time of the endpoint was the date of TR or the date of the last follow-up information (truncated at 40 years of follow-up), whichever came first. We performed time-dependent univariate (log-rank test) and multivariate Cox regression analyses to study the association between time to TR and prognostic factors. The results are presented as hazard ratio (HR) and 95% confidence interval (CI). The assumption of proportional hazard was assessed by Shoenfeld residuals. All P values are based on 2-sided tests, and P < .05 was considered significant. Statistical analysis was performed using statistical package Stata SE, version 14.2 (StataCorp, College Station, TX, USA). 19 
| RESULTS
The final cohort included 123 patients (male/female = 58/ 65) diagnosed with clinical EAF. Nineteen were included in our previous report. 10 Details on patient selection are provided in the flow diagram ( Figure 1 ). The median follow-up time was 11 years (5.8-19.8 25%ile-75%ile; 1626.9 person-years). Ninety-six patients were assessed by an outpatient/inpatient visit (n = 67) or a semistructured telephone interview (n = 29) between December 2014 and December 2016. Twenty-seven patients were not assessed during this period (1 deceased, 26 untraceable). In these cases (median follow-up = 8.8 years, 5.4-1425%ile-75%ile; 292.2 personyears) we considered the seizure frequency in their medical records at their last clinical assessment.
The clinical features of our population are listed in Table 1 . Eighty-four patients (68.3%) were sporadic cases. The remaining 39 (31.7%) were familial; 15 of them (12.2%) belonged to 11 ADEAF pedigrees, whereas the remaining 24 (19.5%) had a family history for another type of epilepsy (focal or generalized). The mean age at onset was 19.3 AE 10.5 years (range = 0.5-57 years). Seizure frequency at onset ranged from monthly to sporadic in most patients (78.1%). The first ictal symptom was auditory aura One patient with data missing. f Intermittent pattern: epilepsy course shows some relapsing periods (relapse is defined as the occurrence of any seizure after a 5-y remission).
in 117 patients, whereas the remaining 6 patients had ictal receptive/global aphasia first, not followed by auditory symptoms. Of 117 patients with auditory aura, 13.7% reported auditory distortions only, 50.4% experienced simple hallucination (even in association with distortions), and 35.9% reported complex hallucinations (even in association with distortions or simple hallucination). Details on the most common types of auditory aura are reported in Table S2 . More than half the individuals experienced at least 1 lifelong seizure during sleep, mostly tonic-clonic seizures. The first symptom (auditory or aphasic aura) was followed by another type of aura in the majority of cases (80%). Aphasia followed auditory symptoms in 35 individuals (Table S1 ).
The mean age at diagnosis of EAF/focal epilepsy was 23.8 AE 10.6 years. The mean time to diagnosis was 4.6 years AE 6.8 (range = 0-39). In 71 (57.7%) patients with a time to diagnosis >1 year, the mean diagnostic delay was 7.8 AE 7.4 years (range = 1-39). Diagnostic delay was ascribable to misdiagnosis (n = 39), absence of medical counseling (n = 28), or both factors (n = 2), whereas no specific reasons for delay were identified in 2 cases. Thirty-three patients were erroneously diagnosed with genetic/idiopathic generalized epilepsy, 2 with anxiety/psychiatric disorders, 1 with syncope, and 1 with isolated epileptic seizure; no specific diagnosis was formulated in the other 2 cases (no drugs were started).
Of the 123 patients, 106 cases (86%) were in remission >1 year at some point. Of these, 71 (67%) subsequently relapsed. The mean duration of the longest remission period was 7.5 AE 5.9 years (median = 5.5, range = 1-31 years). Forty-three of 106 patients in remission for >1 year withdrew AED treatment (most of them under medical supervision). Overall, 30 of 43 patients (70%) who withdrew completely from therapy relapsed.
Ninety-two patients underwent at least 1 genetic test. Six probands (8 patients) had mutations in 1 of the known EAF genes: 1 in LGI1 (previously published 8 ), 3 in SCN1A
(1 previously published ADEAF family 20 and 2 sporadic cases), 1 in DEPDC5 (previously published familial case 20 ) , and 1 in RLN (unpublished familial case).
| TR
The cumulative time-dependent probability of conversion to TR is shown in Figure 2 . Of the 123 patients included, 42 achieved TR at last follow-up (34.1%), and the probability by 10, 20, and 30 years from inclusion was 26.6%, 35.7%, and 51.6%, respectively. Univariate association between TR and possible prognostic factors is reported in Table 1 . Among the TR group, 3 patients (7.1%) had an intermittent course (relapsing-remitting) before attaining TR, whereas the remaining 39 cases showed a remitting pattern.
The mean age at TR was 31.5 AE 13.1 years (range = 13.7-69.1) and the mean disease duration was 12.3 AE 9.9 years. At last follow-up, 30 patients (32.3%) were still on antiepileptic treatment, whereas 12 (28.6%) were not taking any therapy. Among the latter, 11 patients withdrew AEDs after reaching TR according to medical prescription or autonomously. One woman among the TR subjects died at 49 years, after 29 years of disease, from breast cancer. An illustrative case of the TR group is reported as supporting information (Appendix S2).
At last assessment, 81 of 123 patients failed to attain 5-year remission (NTR group, 65.9%). Thirty of them (37%) have been seizure-free for 1-4 years, whereas 51 (62.9%) still had seizures in the year before the last visit. Seventeen of the NTR patients (21%) showed an intermittent (remitting-relapsing) course, whereas the remaining (64 patients, 79%) never experienced TR periods from epilepsy onset (19 cases never experienced remission lasting >1 year).
Among the 48 NTR patients still with seizures, 21 experienced only auras, whereas 25 patients also reported seizures with impairment of awareness or consciousness (2 missing patients). Among these 48 patients, none were off medication, and they took adequate antiepileptic treatment without seizure control; 26 were on monotherapy, whereas 22 were taking a combination of 2-4 AEDs.
At the last follow-up visit, the rate of drug resistance was 35.8% (44 patients), ranging from degree IIa (9 patients) to IIIb (29 patients), according to Perucca. 21 Excluding patients who experienced only auditory auras, the drug resistance rate was 20.3% (25/123). Among patients who were seizure-free at last visit (75 patients), 22 experienced a lifelong period of drug resistance. Overall, 53.6% of patients (66 cases) were classified as drug-resistant during their disease course. Six patients with refractory EAF underwent a comprehensive presurgical assessment (including stereo-electroencephalographic [EEG] monitoring in 4 cases). Three of them underwent surgery: left temporal-insular corticectomy, left anteromedial temporal lobectomy, and left temporaloccipital corticectomy. In all these cases, histological findings were negative. One surgical patient was seizure-free at the last follow-up (Engel class Ia), whereas the remainder still had seizures (Engel classes III and IV).
An illustrative case of the NTR group is reported as supporting information (Appendix S2).
| Predictors of TR
The cumulative time-dependent probability of conversion to TR by single possible prognostic factors is reported in Figure 3 . At univariate analysis, age at onset > 10 years (HR = 3.15, 95% CI = 1.1-8.9, P = .030, Figure 3A) , presence of distortions only as auditory aura (HR = 3.4, 95% CI = 1.3-8.6, P = .010, Figure 3B ), low seizure frequency at onset (HR = 2.1, 95% CI = 1.1-3.9, P = .020, Figure 3C ), and absence of/unremarkable interictal EEG abnormalities (HR = 4.1, 95% CI = 1.3-13.5, P = .019, Figure 3D ) were associated with TR. The presence of mutations in known genes is not associated with a different TR.
The multivariate analysis model including these factors (Table 2 ) disclosed a statistically significant association with TR for age at seizure onset (HR = 3.3, P = .028), distortions only as auditory aura (HR = 2.9, P = .041), and absence of epileptiform activity at interictal EEG (HR = 3.5, P = .041). Their combination into 1 variable with 3 categories disclosed that patients with 3 protective factors for poor prognosis (>10 years at onset, absence of focal epileptiform interictal EEG pattern, only distortions as aura) had an HR for TR of are shown. A, Age at seizure onset (P = .022). The TR rate is significantly higher in patients with age at onset ≥ 10 years (dashed curve) compared to patients with earlier epilepsy onset (continuous curve). B, Type of auditory aura (P = .022). The cumulative probability of TR is significantly higher in patients with distortion only (dotted curve), compared to patients with at least simple hallucination (dashed curve) and patients with at least complex hallucination (continuous curve). C, Seizure frequency at onset (P = .017). The TR rate is significantly higher in patients with low seizure frequency at onset (from sporadic to yearly, dashed curve) compared to patients with high seizure frequency at onset (from monthly to daily, continuous curve). D, Interictal electroencephalographic (EEG) findings (P = .033). The cumulative probability of TR is higher in patients with unremarkable interictal EEG findings (dashed curve) compared to patients with diffuse epileptiform interictal EEG activity (dotted curve) and patients with focal epileptiform interictal EEG activity (continuous curve)
7.1 (95% CI = 1.7-29.8, P = .008), as opposed to patients having 1 or none of them. The intermediate category (2 protective factors) showed a protective trend (HR = 2.5, 95% CI = 0.54-11.2; Figure 4 ).
| DISCUSSION
This is the first study to evaluate the prognostic features of a large cohort of EAF patients after a long-term follow-up.
Most patients are nonlesional sporadic cases (68%). Familial cases represent about 32% of our cohort, but few families have the clear-cut AD inheritance pattern of ADEAF/ ADTLE (12%). Our study showed that only 34.1% of patients achieved TR after a median 11-year follow-up, most with a remitting pattern from disease onset. Most patients not attaining TR showed a continuous pattern with no remissions at all from disease onset, whereas a minority of them had an intermittent condition.
An in-depth qualitative analysis highlighted a heterogeneous spectrum of EAF in terms of outcome and evolution, ranging from mild forms with early TR obtained after the first AED (9%) to severely refractory epilepsy addressed to surgery (5%).
These findings are difficult to compare with other reports, as the prognosis of EAF has not been systematically investigated and information is scant, mainly extrapolated from reports on ADEAF families or from a single case series on sporadic cases. 10 Comparing our results with those of longitudinal cohort studies on epilepsy in general, we found a consistently lower TR rate. Despite major differences in the definitions of remission, duration of followup, and patient selection, these studies report a remission rate ranging from 65% to 85% after 20 years of followup. 22, 23 Cohort studies including focal epilepsies showed 5-year TR rates lower than those of epilepsies in general but with a wide range (37.7%-65%), [24] [25] [26] lacking clear differences between symptomatic and cryptogenic (nonlesional) cases. 26 Prognostic studies on specific focal epileptic syndromes are lacking except for a recent paper on sleeprelated hypermotor epilepsy 27 showing a 22.3% rate of TR at the last assessment, but that series included lesional cases. Some factors can explain the worse prognosis of our cohort with respect to literature data on epilepsies in general and on nonlesional focal epilepsies. First, the NTR group included patients with mild EAF experiencing only auditory auras or rare seizures in which therapy adjustment to obtain a complete remission is not always welcomed because of the low impact of seizures on quality of life balanced against the possible side effects of multiple AEDs or higher AED dosage.
Second, the NTR group included patients who had been seizure-free for <5 years (41%) according to the stringent definition of remission adopted in our cohort. The rationale for this choice stemmed from evidence that brief remissions (1-2 per year) are nonrobust indicators of long-term seizure outcome, as many epilepsies follow a relapsing-remitting course. 17 Moreover, we adopted a definition of relapse as the occurrence of even a single seizure after a 5-year remission, in contrast with other studies that required repeated seizures to define a relapse. Finally, the lack of generalizability of our findings due to a possible referral bias could be hypothesized, as this hospital-based cohort study was carried out in a tertiary center to which patients with refractory epilepsy are referred. However, the inclusion of cases with very mild EAF referred to us for genetic screening allowed us to achieve a population with a considerable variation in epilepsy severity reflecting the broad spectrum of the syndrome. Moreover, to avoid cases initially diagnosed and treated at our center failing to return because of SF, these patients were assessed by telephone interview at last follow-up.
The most important factors affecting remission in our cohort appears to be age at onset < 10 years, complex auditory hallucinations, and focal EEG epileptiform abnormalities.
Age at onset showed a statistically significant association with outcome, as the lower the age at epilepsy onset, the less likely it was for patients to enter TR. Previous studies on mixed epilepsy cohorts published contrasting results concerning age at onset as a factor affecting remission. Early age at onset has been reported as both a negative 29, 30 and positive predictor. 25, 31, 32 Auditory hallucinations influenced the outcome, with the complex type negatively affecting TR. We can speculate that this symptom reflects a wide epileptogenic network involving not only the lateral temporal cortex but also the mesial structures, namely the limbic system. Surgical series have related complex auditory hallucinations to a poor outcome because they underlie a larger epileptic network. [33] [34] [35] Subtle structural impairment of the mesiotemporal lobe has been reported in EAF patients carrying mutations of LGI1.
36
Finally, we found EEG to be associated with prognosis, with focal interictal abnormalities as a negative predictor. Scalp EEG is unrevealing in the majority of EAF cases not only in our series (about 70%) but also in the literature. 6, 10 Clear-cut focal EEG abnormalities in a subgroup of cases with a worse prognosis in our cohort could suggest a subtle structural etiology, namely dysplasia, undetectable with current MRI. Despite continuous improvements in neuroimaging techniques, a significant percentage of malformations in cortical development are not detected by conventional MRI. 37, 38 Recently, both sporadic and familial EAF cases have been reported with mutations in DEPDC5, 20 a gene involved in the mammalian target of rapamycin pathway and associated with focal cortical dysplasia (FCD). 39 The hypothesis that symptomatic cases due to subtle FCD are underestimated in our cohort could partly explain the low remission rate we found. Noticeably, the 3-level ranking of these risk factors, easy to collect even at the first clinical visit, strongly predicted the outcome and may inform clinicians and patients about the long-term prognosis, and aid patient management.
In conclusion, our long-term follow-up data show that EAF has a less favorable outcome than expected from previous studies. However, the prognostic spectrum of the disorder is wide, ranging from mild forms to severely refractory epilepsy addressed to surgery. The outcome appears to be primarily a function of age at onset, type of auditory aura, and scalp EEG findings. Lesional etiology, a major factor known to affect the prognosis of epilepsy in general, could be unrecognized in our cohort because of the limits of conventional neuroimaging in detecting subtle cortical malformations.
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